Format

Send to

Choose Destination
Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Author information

1
The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK.
2
UCL Cancer Institute, University College London, London, WC1E 6DD, UK.
3
Clinical and Translational Sarcoma Research, The Institute of Cancer Research, London, SM2 5NG, UK.
4
The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
5
School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK.
6
Sarcoma Molecular Pathology Laboratory, The Institute of Cancer Research, London, SM2 5NG, UK.
7
Edinburgh Cancer Research Centre, IGMM, University of Edinburgh, Edinburgh, EH4 2XR, UK.
8
Systems Biology Ireland, University College Dublin, Dublin 4, Ireland.
9
The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK. Alan.Ashworth@ucsf.edu.
10
UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, California, 94158, USA. Alan.Ashworth@ucsf.edu.
11
UCL Cancer Institute, University College London, London, WC1E 6DD, UK. s.strauss@ucl.ac.uk.
12
The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK. Chris.Lord@icr.ac.uk.

Abstract

Osteosarcoma (OS) is an aggressive sarcoma, where novel treatment approaches are required. Genomic studies suggest that a subset of OS, including OS tumour cell lines (TCLs), exhibit genomic loss of heterozygosity (LOH) patterns reminiscent of BRCA1 or BRCA2 mutant tumours. This raises the possibility that PARP inhibitors (PARPi), used to treat BRCA1/2 mutant cancers, could be used to target OS. Using high-throughput drug sensitivity screening we generated chemosensitivity profiles for 79 small molecule inhibitors, including three clinical PARPi. Drug screening was performed in 88 tumour cell lines, including 18 OS TCLs. This identified known sensitivity effects in OS TCLs, such as sensitivity to FGFR inhibitors. When compared to BRCA1/2 mutant TCLs, OS TCLs, with the exception of LM7, were PARPi resistant, including those with previously determined BRCAness LoH profiles. Post-screen validation experiments confirmed PARPi sensitivity in LM7 cells as well as a defect in the ability to form nuclear RAD51 foci in response to DNA damage. LM7 provides one OS model for the study of PARPi sensitivity through a potential defect in RAD51-mediated DNA repair. The drug sensitivity dataset we generated in 88 TCLs could also serve as a resource for the study of drug sensitivity effects in OS.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center